Predictive Factors for Prescribing a Mandibular Advancement Device for the Treatment of Obstructive Sleep Apnea
Predictive Morphological Factors for Prescribing a Mandibular Advancement Device in the Therapeutic Approach of Obstructive Sleep Apnea
Study Overview
Status
Conditions
Detailed Description
This study will present 66 adult patients diagnosed with mild or moderate OSA (5 <AHI ≤ 30/h) through polysomnography (PSG) level III, referred from pulmonology, otorhinolaryngology and/or neurology for treatment with MAD, who refuse or do not tolerate the therapeutic approach of CPAP, in the sleep unit of Hospital CUF Tejo. The randomization sequence will be generated by computer and kept confidential, in a sealed and opaque envelope, until the moment of recruitment. There will be 3 study groups:
Group A - Will perform pharyngeal CT with cephalometry and registration in maximum comfortable protrusion (MCP).
Group B - Will perform the DISE with registration in MCP. Group C - Will perform pharyngeal CT with cephalometry and recording in MCP + DISE with recording in MCP
In the first appointment, a complete anamnesis and a clinical examination will be carried out, where several items will be documented: Age, gender, BMI, mallampati index, neck, and waist circumference. The clinical interview will assess daytime sleepiness, nighttime snoring, and the patient's quality of life through the respective questionnaires: the Epworth Sleepiness Scale (ESS), the snoring severity scale (SSS), and the Sleep Apnea Quality of Life Index (SAQLI). Using a Likert scale, the ESS is a quantitative assessment tool for drowsiness or the propensity to fall asleep in eight everyday situations. This instrument has been used in various contexts, populations, and clinical conditions, emphasizing sleep-disordered breathing, namely OSA. The SSS is a three-question questionnaire that assesses the intensity, frequency, and duration of snoring, completed by patients and their bed partners. The SSS is internally consistent across patients, regardless of age and sex, and externally valid, as it has a high correlation with the respiratory disturbance index (RDI), AHI, and ESS. The SAQLI was created as a specific quality-of-life instrument for patients with OSAS. This is a 35-item questionnaire that assesses the adverse impact of OSA in four domains: daily animosity, social interactions, emotional state, and symptoms. Items are scored on a 7-point scale. Still, in the 1st consultation, a PSG level III will be prescribed to assess the possibility of OSA and a CT of the pharynx with cephalometric analysis and recording in MCP to assess the UA and the prognosis of advancement of the mandible in the UA collapse/s.
After confirmation of mild to moderate OSA and application of the inclusion and exclusion criteria, patients will be randomly allocated into 3 study groups, with the randomization sequence generated by computer and kept secret in a sealed and opaque envelope until the time of recruitment:
Group A - Will undergo CT of the pharynx with cephalometry and recording in MCP and will be evaluated as a "poor candidate," "candidate with a moderate resolution," or "good candidate." Group B - Will perform the DISE with registration in MCP and will be evaluated as a "bad candidate," "candidate with a moderate resolution," or "good candidate." Group C - Will undergo pharyngeal CT with cephalometry and recording in MCP + DISE with MCP recording and will be evaluated as a "bad candidate," "candidate with a moderate resolution," or "good candidate."
In the second appointment, impressions will be made for the MAD, and in the third appointment, the MAD will be delivered.
After one month of use and adaptation to the MAD, the three groups will perform a PSG level III, in which the patient will have the MAD placed intra-orally, and the ESS, SSS, and SAQLI questionnaires will be filled out again, and the evaluation of adaptation to the MAD will be carried out (self-report).
After six months of using the MAD, the three groups will again perform a PSG level III, in which the patient will have the DAM placed intra-orally in the same mandibular advancement position that was placed in the previous follow-up. The ESS questionnaires will be completed, including SSS, SAQLI, and assessment of adaptation to the MAD (self-report).
The objective treatment outcome will be based on the PSG level III results with the MAD. An effective response to treatment will be defined as a reduction in AHI after treatment with MAD of 50% compared to baseline, and non-response will be described as a reduction in AHI of <50%. For patients who do not present an effective response in the 1st Follow-up (where PSG level III will be performed one month after adaptation to the MAD), the MAD will be titrated (with more significant mandibular advancement) with the aim of, in the 2nd Follow-up up (where PSG level III will be performed six months after adaptation to the MAD) to obtain an adequate response, always thinking about the most significant possible AHI reduction to improve the patient's quality of life. It will also be analyzed whether the assessment during DISE, that the patient is a "good candidate," "candidate with a moderate resolution," and "poor candidate," is effective after PSG with MAD.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Pedro Cebola, MSc
- Phone Number: +351 969153020
- Email: pc@pedrocebola.com
Study Locations
-
-
-
Lisbon, Portugal, 1350-352
- CUF Tejo Hospital
-
Contact:
- Cristina Caroça, PhD
- Phone Number: +351 917507165
- Email: cristinacaroca@icloud.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients between 18 and 70 years of age with the indication for treatment with mandibular advancement device, who refused or cannot tolerate CPAP;
- Body Mass Index (BMI) between 19 and 34.9 Kg/m2;
- The presence of 8 healthy teeth or more per jaw (upper and lower );
- Maximum mandibular protrusion capacity of at least 6 mm.
Exclusion Criteria:
- Significant nasal obstruction; chronic lung disease;
- Class III or IV congestive heart failure according to the New York Heart Association classification;
- Neuromuscular diseases or previous upper airway surgery unrelated to obstructive sleep apnea;
- Uncontrolled periodontitis;
- Tooth mobility;
- Orthodontic treatment;
- Dental prosthesis wholly or partially removable.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group A - Pharyngeal Computed Tomography Group
22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo pharyngeal CT with cephalometry and with registration in maximum comfortable protrusion (MCP)
|
To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used.
After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
Other Names:
A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD.
The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch).
The adaptation period takes place over one month.
After this adaptation, patients will undergo a new PSG using MAD.
Other Names:
|
|
Group B - Drug-Induced Sleep Endoscopy Group
22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo Drug-induced sleep endoscopy with registration in maximum comfortable protrusion (MCP)
|
A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD.
The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch).
The adaptation period takes place over one month.
After this adaptation, patients will undergo a new PSG using MAD.
Other Names:
The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room.
This technique is complemented with bite registration (MCP).
Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL).
The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS).
In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
Other Names:
|
|
Group C - Pharyngeal Computed Tomography and Drug-Induced Sleep Endoscopy Group
22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo a pharyngeal computed tomography + Drug-induced sleep endoscopy with registration in maximum comfortable protrusion (MCP)
|
To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used.
After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
Other Names:
A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD.
The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch).
The adaptation period takes place over one month.
After this adaptation, patients will undergo a new PSG using MAD.
Other Names:
The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room.
This technique is complemented with bite registration (MCP).
Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL).
The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS).
In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the apnea-hypopnea index
Time Frame: Before making and starting to use the MAD and one and six months after
|
The apnea-hypopnea index will be registered with the level III polysomnography and we will evaluate after using the MAD if there were improvements or not, relating to the predictors that we analyzed before.
|
Before making and starting to use the MAD and one and six months after
|
|
Changes in upper airway collapse analyzed by CT Pharyngeal
Time Frame: Through study completion, an average of six months
|
the prognosis for the use of a MAD using the MCP recording and VOTE scoring system: when the upper airway collapse has entirely resolved (no residual collapse at any level of the upper airway), with the bite registration in MCP, the patient will be considered a "Good Candidate."
Suppose there is only partial resolution (improvement, but with the residual or multilevel collapse of the upper airway) with the bite registration in PMC.
In that case, you will qualify as a "moderately resolved candidate."
If upper airway collapse remains unchanged or worsens with PMC bite registration, patients will be considered a "poor candidate."
|
Through study completion, an average of six months
|
|
Changes in Upper Airway collapse analyzed by DISE
Time Frame: through study completion, an average of six months
|
Evaluation of the prognosis for the use of a MAD, we will use the mandibular advancement record in MCP.
The VOTE classification: when the UA collapse is completely resolved (no residual collapse at any level of the upper airway), and there is no snoring, with the bite registration in MCP, the patient will be considered a "Good Candidate."
Suppose there is only partial resolution (improvement, but with the residual or multilevel collapse of the UA) and some snoring with the bite registration in MCP.
In that case, he will qualify as a "candidate with moderate resolution."
If UA collapse remains unchanged or worsens with MCP bite registration and still snoring, patients will be considered a "bad candidate."
|
through study completion, an average of six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective assessment of daytime sleepiness
Time Frame: Before making and starting to use the MAD and one and six months after
|
The subjective evaluation will be done through a validated questionnaire: Epworth Sleepiness Scale (ESS).
The ESS asks the respondent to rate on a 4-point scale (0-3).
The higher the score, the more severe the daytime sleepiness
|
Before making and starting to use the MAD and one and six months after
|
|
Subjective assessment of quality of life
Time Frame: Before making and starting to use the MAD and one and six months after
|
The subjective evaluation will be carried out through a validated questionnaire - Sleep Apnea Quality of Life Index (SAQLI) -a 35-item questionnaire that assesses the adverse impact of OSA.
Items are scored on a 7-point scale.
|
Before making and starting to use the MAD and one and six months after
|
Collaborators and Investigators
Investigators
- Study Director: Cristina Manso, PhD, Egas Moniz School of Health and Science
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Signs and Symptoms, Respiratory
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Apnea
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Hypnotics and Sedatives
- Propofol
Other Study ID Numbers
- PHDPMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Apnea, Obstructive
-
Hospital Felicio RochoNot yet recruitingSleep Apnea/Hypopnea Syndrome | Sleep Apnea Syndrome, Obstructive | Sleep Apnea Syndrome (OSAS) | Sleep Apnea - Obstructive
-
Isabel Moreno HayAmerican Academy of Dental Sleep MedicineRecruitingObstructive Sleep Apnea (SAOS) | Obstructive Sleep Apnea (OSAS)United States
-
Mayo ClinicEnrolling by invitationObstructive Sleep Apnea | OSA | Obstructive Sleep Apnea (OSA)United States
-
Hospices Civils de LyonNot yet recruitingObstructive Sleep ApneaFrance
-
University Hospital, AntwerpNot yet recruiting
-
Nyxoah Inc.Not yet recruitingObstructive Sleep ApneaUnited States
-
Restera, Inc.RecruitingObstructive Sleep ApneaAustralia
-
China Medical University HospitalRecruiting
-
ProSomnus Sleep TechnologiesActive, not recruiting
Clinical Trials on Pharyngeal Computed Tomography
-
Virginia Commonwealth UniversityCompleted
-
University of PadovaUniversity Hospital PadovaRecruitingCraniocerebral Trauma | Platelet Aggregation InhibitorsItaly
-
Stanford UniversitySiemens Healthcare QTCompletedMetastatic Renal Cell CancerUnited States
-
University Hospital, AntwerpCompleted
-
M.D. Anderson Cancer CenterGE HealthcareCompletedLung CancerUnited States
-
Xuzhou Central HospitalCompletedLung Cancer | Lung; NodeChina
-
Virginia Commonwealth UniversityTerminated
-
University Hospital, GhentEAU Young Academic Urologists Urolithiasis and Endourology Working Group; European... and other collaboratorsEnrolling by invitationNephrolithiasis | Urolithiasis | UreterolithiasisBelgium
-
University Hospital, ToulouseCompletedSinonasal PathologiesFrance
-
University of ZurichRecruitingPneumonia | Lung Cancer | Radiation Exposure | Lung EmbolismSwitzerland